Literature DB >> 18317013

Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients.

Florence Damond, Sylvie Lariven, Benedicte Roquebert, Sylvia Males, Gilles Peytavin, Genevieve Morau, Daniel Toledano, Diane Descamps, Francoise Brun-Vezinet, Sophie Matheron.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18317013     DOI： 10.1097/QAD.0b013e3282f51203

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  19 in total

1.  Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Christopher G Zavala; Jennifer Song; Khardiata Mbaye Diallo; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 2.  Antiretroviral drug resistance in human immunodeficiency virus type 2.

Authors:  Michel L Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

Review 3.  HIV-1 antiretroviral drug therapy.

Authors:  Eric J Arts; Daria J Hazuda
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

4.  HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen?

Authors:  Daniela Francisci; Laura Martinelli; Liliana E Weimer; Maurizio Zazzi; Marco Floridia; Giulia Masini; Franco Baldelli
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 5.  Update on human immunodeficiency virus (HIV)-2 infection.

Authors:  Omobolaji T Campbell-Yesufu; Rajesh T Gandhi
Journal:  Clin Infect Dis       Date:  2011-03-15       Impact factor: 9.079

6.  A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.

Authors:  Selly Ba; Dana N Raugi; Robert A Smith; Fatima Sall; Khadim Faye; Stephen E Hawes; Papa Salif Sow; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

7.  Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.

Authors:  Robert A Smith; Dana N Raugi; Nancy B Kiviat; Stephen E Hawes; James I Mullins; Papa S Sow; Geoffrey S Gottlieb
Journal:  AIDS       Date:  2011-11-28       Impact factor: 4.177

8.  Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.

Authors:  Sabelle Jallow; Abraham Alabi; Ramu Sarge-Njie; Kevin Peterson; Hilton Whittle; Tumani Corrah; Assan Jaye; Matthew Cotten; Guido Vanham; Samuel J McConkey; Sarah Rowland-Jones; Wouter Janssens
Journal:  J Clin Microbiol       Date:  2009-05-06       Impact factor: 5.948

9.  In Vitro Antiviral Activity of Cabotegravir against HIV-2.

Authors:  Robert A Smith; Vincent H Wu; Christopher G Zavala; Dana N Raugi; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

10.  A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.

Authors:  Geoffrey S Gottlieb; Serge-Paul Eholié; John N Nkengasong; Sabelle Jallow; Sarah Rowland-Jones; Hilton C Whittle; Papa Salif Sow
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.